profit from every $100 of sales.
$0$100
Apellis Pharmaceuticals
We have no price for Apellis Pharmaceuticals since 15 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$41.03+0.00% today
+68.4% since Oct 6, 25
1-year low $16.971-year high $41.12
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $234.62 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Apellis Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $75.4 million in 2022 to $1.00 billion in 2025, with $22.4 million of profit last year.
SalesProfit
Apellis Pharmaceuticals vs. similar companies
Apellis Pharmaceuticals grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Apellis Pharmaceuticals | 234.6× · Very expensive | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Apellis Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 75 | 397 | 781 | 1,004 | |
| 70 | 338 | 664 | 902 | |
| -595 | -517 | -165 | 55 | |
| -617 | -495 | -155 | 70 | |
| -652 | -529 | -198 | 22 | |
| -6.15 | -4.45 | -1.60 | 0.18 | |
| 92.5% | 85.2% | 84.9% | 89.8% | |
| -788.4% | -130.4% | -21.1% | 5.5% | |
| -864.7% | -133.3% | -25.3% | 2.2% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 760 | 789 | 885 | 1,075 |
| Cash | 552 | 351 | 411 | 466 |
| Total debt | 113 | 111 | 470 | 474 |
| Total liabilities | 590 | 594 | 657 | 705 |
| 170 | 195 | 229 | 370 | |
| 106 | 119 | 124 | 130 | |
| -173.0% | -128.5% | -17.7% | 6.4% | |
| -383.9% | -271.8% | -86.6% | 6.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -514 | -595 | -88 | 45 | |
| 2 | 1 | 0 | 0 | |
| -515 | -596 | -88 | 45 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 91 | 106 | 114 | 104 |
Valuation
- 234.6×
- –
- –
- 12.5×
- 5.2×
- 116.7×
- 75.2×
- 0.9%
- 0.4%
- 0.0%
Profitability
- 89.8%
- 5.5%
- 2.2%
- 16.3%
- 18.1%
- -122.4%
- 39.7%
- 12.3%
- 20.7%
- 25.9%
Growth
- +137.0%
- –
- +151.0%
- –
- +10.5%
Financial health
- 0.4×
- 1.15
- 43.9%
- 3.8×
- 3.63
- 3.16
- 1.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 948
Bottom 41%of 871
Bottom 1%of 560
Top 4%of 868
Bottom 47%of 985
What analysts expect
- Average price target
- $33.40
- Range
- $19.00 – $48.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.15 | -0.38 | +139.5% |
| Feb 24, 2026 | -0.47 | -0.39 | −20.5% |
| Oct 30, 2025 | 1.67 | 1.03 | +62.1% |
| Jul 31, 2025 | -0.33 | -0.44 | +25.0% |
| May 7, 2025 | -0.74 | -0.36 | −105.6% |
| Feb 28, 2025 | -0.29 | -0.37 | +21.6% |
| Nov 5, 2024 | -0.46 | -0.32 | −43.8% |
| Aug 1, 2024 | -0.28 | -0.33 | +15.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
37No pass
Philip Fisher
50No pass
Peter Lynch
49No pass
Joel Greenblatt
16No pass
Charlie Munger
44No pass
Terry Smith
51No pass
Questions about Apellis Pharmaceuticals
Is Apellis Pharmaceuticals a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Apellis Pharmaceuticals AI analysis
What does Apellis Pharmaceuticals do?
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. It is in Biotechnology, based in Waltham, MA, United States, with 733 employees.
Does Apellis Pharmaceuticals pay a dividend?
No. Apellis Pharmaceuticals does not pay a dividend at the moment.
Is Apellis Pharmaceuticals stock halal?
Yes. Apellis Pharmaceuticals passes our halal screen: its business is permitted and its debt is 9% of its market value, under the 30% limit. How we check
Who are Apellis Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Apellis Pharmaceuticals's.
Prices: daily closes to May 15, 2026. Fundamentals: company reports via invest-like data.